Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Comparative Pharmacokinetics of Trientine Dihydrochloride Capsules: A Randomized, Open-Label, Reference-Controlled, Two-Period Crossover Study in Healthy Volunteers
Christian J. Hartmann; Frank Tacke; Isabelle Mohr; Michael Praktiknjo; Martin Jankofsky; Steffen Wahler; Karl Heinz WeissShow moreShow less
1. University Clinic Duesseldorf, Institute of Clinical Neuroscience and Medical Psychology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; 2. Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany; 3. Zentrum Innere Medizin, Medizinische Klinik IV, Gastroenterologie und Hepatologie, Universitätsklinikum Heidelberg, Heidelberg, Germany; 4. Medizinische Klinik B, Universitätsklinikum Münster, Münster, Germany; 5. Pediatric Hepatology, University Children’s Hospital Hamburg-Eppendorf, Hamburg, Germany; 6. St. Bernward GmbH, Hamburg, Germany; 7. Universitätsklinik Heidelberg-Innere Medizin Klinik Salem, Heidelberg, GermanyShow moreShow less
Optimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway
Giancarlo Di Gennaro; Paolo Bonanni; Francesco Deleo; Antonio Gambardella; Roberto Michelucci; Giada Pauletto; Nicola Specchio; Alfredo D’AnielloShow moreShow less
1. IRCCS NEUROMED, Pozzilli, Italy; 2. IRCCS E. Medea Scientific Institute, Epilepsy Unit, Conegliano, Italy; 3. Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 4. Azienda Ospedaliero-Universitaria “Renato Dulbecco” di Catanzaro, Catanzaro, Italy; 5. IRCCS-Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 6. SOC Neurologia, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 7. Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesu’ Children’s Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies, EpiCARE, Rome, Italy; 8. University Hospitals, KU Leuven, Leuven, BelgiumShow moreShow less
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
Sudershan Kumar; Arshad Khuroo; Sanjay Jagannath Gurule; Sachin Mehra; Hari Krishan Tiwari; Y. Zala; Venkata Rama Rao Kamala; Madhu Kandukuri; Shruti Dharmadhikari; Prashant Devkare; Chintan KhandhediaShow moreShow less
1. Clinical Pharmacology and Pharmacokinetics, Sun Pharmaceutical Industries Limited, Gurgaon, India; 2. Clinical Pharmacology Unit, Sun Pharmaceutical Industries Limited, Gurgaon, India; 3. Formulation Department, Sun Pharma Advanced Research Company (SPARC) Ltd, Mumbai, India; 4. Medical Affairs and Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India; 5. Medical Affairs and Clinical Research, Sun Pharmaceutical Industries Limited, Mumbai, IndiaShow moreShow less
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
Si-kai Wang; Wei Li; Miao-miao Guo; Man Han; Ze-chun Long; Jin-hui He; Xiang-yang Xie; Yuan Zeng; Hui LiuShow moreShow less
1. School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China; 2. Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, China; 3. Department of Pharmacy, Jingmen People’s Hospital, Jingmen, China; 4. School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, China; 5. School of Pharmacy, Hubei University of Science and Technology, Xianning, China; 6. College of Nursing and Health Management and College of Life Science and Chemistry, Wuhan Donghu University, Wuhan, China; 7. Department of Pharmacy, General Hospital of Central Theater Command, Wuhan, ChinaShow moreShow less
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
Javier Molina-Cerrillo; Arantzazu Sierra-Ramirez; José L. López-Aceituno; Marinela Méndez-Pertuz; Teresa Alonso-Gordoa; Michael Linnebacher; Matteo Santoni; Pablo J. Fernandez-Marcos; Enrique GrandeShow moreShow less
1. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 2. Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, Madrid, Spain; 3. CNIO Cancer Center, Madrid, Spain; 4. Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, Rostock, Germany; 5. Medical Oncology Unit, Macerata Hospital, Macerata, Italy; 6. Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, SpainShow moreShow less
Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies
Bolin YangShow moreShow less
1. Department of Colorectal Surgery/IBD Center, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaShow moreShow less
FAQ
How long does DRUGS IN R&D take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for DRUGS IN R&D. The fastest paper went from submission to acceptance in 71 days (Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study, received 2026-03-24, accepted 2026-06-03); the slowest took 314 days. The average is 186.9 days and the median is 187 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
